about
Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiencyEffects of exenatide in a morbidly obese patient with type 2 diabetesPharmacological treatment of obesity in children and adolescents: present and futureGut peptide GLP-1 and its analogue, Exendin-4, decrease alcohol intake and rewardPeripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4.Induction of Energy Expenditure by Sitagliptin Is Dependent on GLP-1 ReceptorIncretin therapy--present and future.Glucagon-like peptide 1 receptors in nucleus accumbens affect food intake.Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disordersPeptide hormones regulating appetite--focus on neuroimaging studies in humans.Novel GLP-1 receptor agonists for diabetes.The therapeutic potential of GPR119 agonists for type 2 diabetes.The endocrinology of food intake.Long-term tolerance and efficacy of adjunctive exenatide therapy on glycaemic control and bodyweight in type 2 diabetes: a retrospective study from a specialist diabetes outpatient clinic.Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries.The GLP-1 analogue exenatide improves hepatic and muscle insulin sensitivity in diabetic rats: tracer studies in the basal state and during hyperinsulinemic-euglycemic clamp.The influence of incretin mimetics on cardiovascular risk factors in diabetes.Comparative effects of the long-acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats.Ultra-high-performance liquid chromatography for the determination of exenatide in monkey plasma by tandem quadrupole mass spectrometry.Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes.
P2860
Q28740948-1013FF21-7A04-4CB6-8ECD-4D6D4A8DFE02Q33785151-4EE5A3DD-1EDF-4A43-AFD8-ACA985E22D96Q34442880-926AE7F5-DFFD-4950-9A2D-2D653060118DQ34685472-FF0DD6D4-DEDE-4EA4-9C96-AEFCB2BAD7BAQ35110843-A3360374-491C-47B8-B14A-8C8E495E5DE3Q35621637-4E854F32-0B73-47D0-93A3-75DA9C2396BDQ35760283-E4B3DE80-5D50-4212-A087-8A799DE6E68DQ35893496-E4833B0D-9435-4021-9A64-19C4DCF6A376Q36166654-36DB9735-0EF1-4F49-8138-388AD682F070Q37835786-F9147861-96D3-4384-A5AF-755B967B7EFBQ37960149-2247B391-5F57-4C6B-9B06-DC480D74998BQ37980173-F3BCF99D-42E5-403E-B54C-46F06E996F6DQ38123372-0CDBD32C-2C77-44E8-B075-101C57E1CD39Q38216039-F9AFD016-95B2-42C4-A1C8-6DF7B31517CFQ38718345-2C665795-F920-4C6C-AF60-884631130B78Q42099874-81390FAC-B9CA-48D9-8C0C-1C67539071B7Q42584383-FE28D6EB-3EBC-4A65-89AC-493803F0E00BQ47385994-EEFA5485-2DA8-4102-9B1F-DDCD608ECAC4Q49474845-E2AFF846-A7B4-4879-A432-DDA4FB27A893Q51322701-65652973-15E5-4148-AF70-476E0764070F
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Exenatide and weight loss.
@en
Exenatide and weight loss.
@nl
type
label
Exenatide and weight loss.
@en
Exenatide and weight loss.
@nl
prefLabel
Exenatide and weight loss.
@en
Exenatide and weight loss.
@nl
P1433
P1476
Exenatide and weight loss
@en
P2093
Dale A Schoeller
Roger Kulstad
P304
P356
10.1016/J.NUT.2009.07.008
P577
2010-03-01T00:00:00Z